New frontiers in oncology: Biosimilar monoclonal antibodies for the treatment of breast cancer

Expert Review of Anticancer Therapy

Volumn 15, Issue 3, 2015, Pages 331-338

  Thill, Marc ^a  

^a AGAPLESION MARKUS KRANKENHAUS   (Germany)

Author keywords

biosimilar; biosimilar antibody; breast cancer; CT P6; Herceptin; monoclonal antibody; trastuzumab

Indexed keywords

ABP 980; BCD 022; CANMAB; CMAB 302; ERYTHROPOIETIN; FILGRASTIM; GB 221; HERTRAZ; INFLIXIMAB; PF 05280014; SB 3; TRASTUZUMAB; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; BIOSIMILAR AGENT; MONOCLONAL ANTIBODY;

BREAST CANCER; BREAST METASTASIS; DRUG APPROVAL; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; EPIDERMAL GROWTH FACTOR RECEPTOR 2 POSITIVE BREAST CANCER; HUMAN; IMMUNOGENICITY; IN VITRO STUDY; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; REVIEW; RISK MANAGEMENT; TREATMENT OUTCOME; ANIMAL; BREAST NEOPLASMS; DRUG DESIGN; EUROPE; FEMALE; PATHOLOGY;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; BIOSIMILAR PHARMACEUTICALS; BREAST NEOPLASMS; DRUG APPROVAL; DRUG DESIGN; EUROPE; FEMALE; HUMANS;

EID: 84923920535     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.2015.993318     Document Type: Review

References (43)

1. Top 20 best-selling drugs of 2012. Genetic engineering &biotechnology news. 2013. Available from: www.genengnews.com/insight-And-intelligenceand153/top-20-bestselling-drugs-of-2012/77899775/?page=1 [Last accessed 17 April 2014]
2. Dawood S, Broglio K, Buzdar AU, et al. Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review. J Clin Oncol 2010; 28: 92-8
3. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344: 783-92
4. Cobleigh MA, Vogel CL, Tripathy D, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999; 17: 2639-48
5. Herceptin European Public Assessment Report. European Medicines Agency, 2014. Available from: www.ema.europa.eu/docs/en-GB/document-library/EPAR---Product-Information/human/000278/WC500074922.pdf [Last accessed 27 October 2014]
6. Baselga J, Cortes J, Kim SB, et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 2012; 366: 109-19
7. Ismael G, Hegg R, Muehlbauer S, et al. Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I-III breast cancer (HannaH study): a phase 3 open-label multicentre randomised trial. Lancet Oncol 2012; 13: 869-78
8. Weise M, Bielsky MC, De Smet K, et al. Biosimilars: what clinicians should know. Blood 2012; 120: 5111-17
9. Guideline on similar biological medicinal products [draft guidance]. European Medicines Agency. 2013; Available from: www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2013/05/WC500142978.pdf [Last accessed 30 March 2014]
10. What you need to know about biosimilar medicinal products A consensus information document. European Commission. 2013. Available from: ec. europa.eu/enterprise/sectors/healthcare/files/docs/biosimilars-report-en.pdf [Last accessed 30 March 2014]
11. Shuptrine CW, Surana R, Weiner LM. Monoclonal antibodies for the treatment of cancer. Semin Cancer Biol 2012; 22: 3-13
12. Revers L, Furczon E. An introduction to biologics and biosimilars. Part II. subsequent entry biologics: Biosame or biodifferent? Can Pharmacists J 2010; 143: 184-91
13. Guideline on similar biological medicinal products containing monoclonal antibodies: non-clinical and clinical issues. European Medicines Agency. 2012. Available at www. ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2012/06/WC500128686.pdf [Last accessed 30 March 2014]
14. Guideline on immunogenicity assessment of monoclonal antibodies intended for in vivo clinical use. European Medicines Agency. 2012. Available from: www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2012/06/WC500128688.pdf [Last accessed 30 March 2014]
15. Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues. European Medicines Agency. 2006. Available from: www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2009/09/WC500003920.pdf [Last accessed 30 March 2014]
16. Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: quality issues. European Medicines Agency. 2006. Available from: www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2009/09/WC500003953.pdf [Last accessed 30 March2014]
17. Cortes J, Curigliano G, Dieras V. Expert perspectives on biosimilar monoclonal antibodies in breast cancer. Breast Cancer Res Treat 2014; 144: 233-9
18. Burzykowski T, Buyse M, Piccart-Gebhart MJ, et al. Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate endpoints in metastatic brease cancer. J Clin Oncol 2008; 26: 1987-92
19. Blum JL, Jones SE, Buzdar AU, et al. Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol 1999; 17: 485-93
20. Kuerer HM, Newman LA, Smith TL, et al. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol 1999; 17: 460-9
21. Cortazar P, Zhang L, Untch M, et al. Pathological complete response and long-Term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet 2014; 384: 164-72
22. Cary LA, Winer EP. Defining success in neoadjuvant breast cancer trials. Lancet 2014; 384: 115-16
23. Guideline on good pharmacovigilance practices (GVP). European Medicines Agency. 2012. Available from: www.ema. europa.eu/docs/en-GB/document-library/Scientific-guideline/2012/02/WC500123202.pdf [Last accessed 28 April 2014]
24. European Commission Directive 2012/52/EU. Available from: ec.europa.eu/health/cross-borderčare/docs/impl-directivépresciptions-2012-en.pdf [Last accessed 28 April 2014]
25. Mellstedt H. Clinical considerations for biosimilar antibodies. Eur J Cancer Suppl 2013; 11: 1-11
26. Remsima European Public Assessment Report. European Medicines Agency, 2013. Available from: www.ema.europa.eu/docs/en-GB/document-library/EPAR---Product-Information/human/002576/WC500150871.pdf [Last accessed 12 April 2014]
27. Jackisch C, Scappaticci FA, Heinzmann D, et al. Neoadjuvant breast cancer treatment as a sensitive setting for trastuzumab biosimilar development and extrapolation. Future Oncol 2014; 28: 1-11
28. Im Y-H, Odarchenko P, Grecea D, et al. Double-blind, randomized, parallel group, phase III study to demonstrate equivalent efficacy and comparable safety of CT-P6 and trastuzumab, both in combination with paclitaxel, in patients with metastatic breast cancer (MBC) as first-line treatment. J Clin Oncol 2013; 31(suppl): Abstract 629
29. Celltrion's Herzuma (trastuzumab) receives Korea MFDS approval. Celltrion, 2014. Available at www.celltrion.com/en/company/noticéview.asp?idx=425&code=ennews&intNowPage=1&menu-num=&align-year=all [Last accessed 21 April 2014]
30. Indian court issues injunction on Biocon, Mylan's Herceptin biosimilars after challenge by Roche. First World Pharma, 2014. Available from: www. firstwordpharma.com/node/1185990#axzz35RaF79J4 [Last accessed 10 May 2014]
31. A safety and efficacy study of BCD-022 with paclitaxel compared to Herceptin with paclitaxel in HER2-positive metastatic breast cancer patients. U.S. National Institutes of Health. 2014. Available from: clinicaltrials.gov/ct2/show/NCT01764022 [Last accessed 10 May 2014]
32. Amgen's master plan to generate biosimilar blockbusters. Seeking Alpha. 2013. Available from: seekingalpha.com/article/1275871-Amgens-master-plan-To-generate-biosimilarblockbusters [Last accessed 10 May 2014]
33. Efficacy and safety study of ABP 980 compared with trastuzumab in subjects with HER2 positive early breast cancer (Lilac). U.S. National Institutes of Health. 2014. Available from: clinicaltrials.gov/ct2/show/NCT01901146 [Last accessed 29 June 2014]
34. Genor Biopharma and BIOCND form partnership to develop Genor's mAb biosimilars for international market. First World Pharma. 2013. Available from: www. firstwordpharma.com/node/1098751#axzz2hGQakQmt [Last accessed 10 May 2014]
35. Yin D, Barker KB, Li R, et al A phase I pharmacokinetics trial comparing PF-05280014 (a potential biosimilar) and trastuzumab in healthy volunteers (REFLECTIONS B327-01). J Clin Oncol 2013; 31(suppl): abstract 612
36. A study of PF-05280014 [Trastuzumab-Pfizer] or Herceptin- [Trastuzumab-EU]plus paclitaxel in HER2 positive first line metastatic breast cancer treatment (REFLECTIONS B327-02). U.S. National Institutes of Health. 2014. Available from: clinicaltrials.gov/ct2/show/NCT01989676[Last accessed 29 June 2014]
37. Hospira wins Herceptin patent suit in UK, paving way for biosim. Fierce Pharma. 2014. Available from: www.fiercepharma.com/story/hospira-wins-herceptin-patentsuit-uk-paving-way-biosim/2014-04-10 [Last accessed 30 June 2014]
38. Dr Reddy's, Intas to tap India's Herceptin market. Business Standard. 2013. Available from: www.business-standard.com/article/companies/dr-reddy-s-intas-To-Tap-india-sherceptin-market-113082000798-1.html [Last accessed 10 May 2014]
39. Biosimilars: 10 drugs to watch. Genetic Engineering &Biotechnology News. 2013. Available from: www.genengnews.com/keywordsandtools/print/3/31123/[Last accessed 10 May 2014]
40. A study to compare the effect of SB3 and Herceptin- in women with HER2 positive breast cancer. U.S. National Institutes of Health. 2014. Available from: clinicaltrials.gov/ct2/show/NCT02149524 [Last accessed 29 June 2014]
41. Study of Cipterbin-, used alone or with vinorelbine in patients with HER2/neuoverexpressed metastatic breast cancer. U.S. National Institutes of Health. 2011. Available from: clinicaltrials.gov/ct2/show/NCT01439191 [Last accessed 29 June 2014]
42. Choy E, Jacobs IA. Biosimilar safety considerations in clinical practice. Semin Oncol 2014; 41: S3-14
43. Verma S, Miles D, Gianni L, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 2012; 367: 1783-91